GCF IL-17 Levels and Oxidative Status of Smoking and Non-smoking Individuals With Periodontitis

Chronic Periodontitis Clinical Trial

— GCF  

Official title:

Smoking Effects on GCF GCF IL-17A AND IL-17 Levels and Oxidative Status of Patients Receiving Periodontal Treatment

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04115176
• Other study ID #: PYO.DIS.1901.17.002
• Status: Completed
• Start date: October 10, 2017
• Est. completion date: July 10, 2019

Study information

• Verified date: October 2019
• Source: Ondokuz Mayis University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study was performed to evaluate the effects of both periodontal treatment and smoking on the gingival crevicular fluid(GCF) levels of interleukin (IL)-17A, IL-17E, Total oxidative stress(TOS) and total antioxidant capasity(TAOC) in smoking and non-smoking patients with severe chronic periodontitis.

Systemically healthy 15 smoker,15 non-smoker with chronic periodontitis were attended for the study. Periodontal status were determined by recording periodontal clinical measurements. GCF samples were collected at the baseline, at the end of initial periodontal treatment and 4 weeks after periodontal flap surgery. The data were tested statistically by the Student t and paired sample t tests.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: July 10, 2019
• Est. primary completion date: July 10, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 35 Years to 60 Years

Eligibility

Inclusion Criteria:

• individuals aged ?35 years and having =16 teeth diagnosed as chronic periodontitis

• not received any periodontal therapy within the previous 6 months;

• not received antibiotic/anti-inflammatory drug treatment within the previous 6 months.

Exclusion Criteria:

• receiving medical treatment for cancer, rheumatoid arthritis, diabetes mellitus, cardiovascular disease, or any other systemic disease;

• being pregnant or being in the period of menopause or lactation;

• receiving any drug therapy that might affect the clinical characteristics of periodontitis;

• usage of systemic antimicrobials during the 6 weeks prior to data collection

Related Conditions & MeSH terms

• Chronic Periodontitis
• Periodontitis
• Smoking, Cigarette

Locations

Country	Name	City	State
Turkey	Müge Lütfioglu	Samsun	Atakum

Sponsors (1)

Lead Sponsor	Collaborator
Ondokuz Mayis University

Country where clinical trial is conducted

Turkey, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	GCF IL-17A VOLUME	IL-17A is a cytokine present in gingival crevicular fluid. Its volume calculated as microliter and changes due to inflammation caused by periodontal disease.	GCF sampling was performed prior to periodontal treatment , 4 weeks after completion of initial periodontal treatment, and 4 weeks after periodontal flap surgery .
Primary	GCF IL-17E VOLUME	IL-17E is a cytokine present in gingival crevicular fluid. Its volume calculated as microliter and changes due to inflammation caused by periodontal disease.	GCF sampling was performed prior to periodontal treatment , 4 weeks after completion of initial periodontal treatment, and 4 weeks after periodontal flap surgery .
Primary	GCF TOTAL OXIDATIVE STRESS (TOS) LEVEL	TOS is the measurement of oxidative stress amount and given as mmol/L unit. Its amount changes due to inflammation caused by periodontal disease.	GCF sampling was performed prior to periodontal treatment , 4 weeks after completion of initial periodontal treatment, and 4 weeks after periodontal flap surgery .
Primary	GCF TOTAL ANTIOXIDANT CAPASITY (TAOC)	TAOC is the antioxidant amount measured and given as µmol H2O2 Eq/L unit. Its amount changes due to inflammation caused by periodontal disease.	GCF sampling was performed prior to periodontal treatment , 4 weeks after completion of initial periodontal treatment, and 4 weeks after periodontal flap surgery .